Early molecular imaging response assessment based on determination of total viable tumor burden in [(68)Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [(177)Lu]Lu-PSMA-617 radioligand therapy

PURPOSE: In patients with metastatic castration-resistant prostate cancer (mCRPC) treated with prostate-specific membrane antigen-targeted radioligand therapy (PSMA-RLT), the predictive value of PSMA PET/CT-derived response is still under investigation. Early molecular imaging response based on tota...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosar, Florian, Wenner, Felix, Khreish, Fadi, Dewes, Sebastian, Wagenpfeil, Gudrun, Hoffmann, Manuela A., Schreckenberger, Mathias, Bartholomä, Mark, Ezziddin, Samer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940840/
https://www.ncbi.nlm.nih.gov/pubmed/34725725
http://dx.doi.org/10.1007/s00259-021-05594-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940840/
https://www.ncbi.nlm.nih.gov/pubmed/34725725
http://dx.doi.org/10.1007/s00259-021-05594-8

Ejemplares similares